New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials

Record Status
This is a systematic review that meets the criteria for inclusion on DARE.

Bibliographic details

PubMedID
16088965

DOI
10.1002/cncr.21339

Indexing Status
Subject indexing assigned by NLM

MeSH
Aged; Androstenedione /administration & dosage /analogs & derivatives; Antineoplastic Combined Chemotherapy Protocols /therapeutic use; Aromatase Inhibitors /therapeutic use; Breast Neoplasms /drug therapy /mortality /pathology; Carcinoma /drug therapy /mortality /secondary; Clinical Trials, Phase III as Topic; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Fadrozole /administration & dosage; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent /drug therapy /mortality /pathology; Nitriles /administration & dosage; Postmenopause; Probability; Prognosis; Remission Induction; Risk Assessment; Survival Analysis; Triazoles /administration & dosage

AccessionNumber
12005001376

Date bibliographic record published
24/04/2006